Skip to main content

Aviado · Research

Longevity Daily

Sunday, November 15, 2026

Today's Brief

Today's edition centers on cognitive health, with a truly alarming lead: the glucosamine supplement that millions rely on for joint pain has been linked to faster Alzheimer's progression in a Nature Metabolism study. Johns Hopkins adds to the brain story, pinpointing two regions that signal Alzheimer's risk a full decade before the hippocampus shows changes. In supplements, the STAMINA trial delivers a rare clinical win for a vascular-aging compound, and Aviado Research explains why DHA's inflammation benefits require patience — it's remodeling your cell membranes, not just circulating through your blood.

10 stories5 peer-reviewed2 trials1 Aviado original

Cognitive Health & Neuroprotection

Must ReadNature Metabolism· 2026-11-14

Popular Joint Supplement Glucosamine Linked to Faster Alzheimer's Progression

If you take glucosamine for your joints, this study demands your attention. A large retrospective analysis of patient health records — corroborated by experiments on human brain tissue and Alzheimer's mouse models — found that glucosamine appears to accelerate disease progression, with the findings published in Nature Metabolism. Researchers believe the culprit is disrupted glucose metabolism: glucosamine can interfere with how cells process sugar, a pathway increasingly implicated in neurodegeneration. The results are preliminary and not yet validated in a human clinical trial, but the scale of the data and biological plausibility make this a conversation worth having with your doctor before your next dose.

Read more →
New ResearchWomen's Health Magazine· 2026-11-14

Osteoporosis Drugs Associated With 24% Lower Dementia Risk in Large Analysis

Nitrogen-containing bisphosphonates (NBPs) — the most commonly prescribed class of osteoporosis drugs — are associated with a 24% reduction in dementia risk in a new large-scale study. The connection may lie in these drugs' anti-inflammatory or bone-metabolic properties affecting the brain. This is an association study, not proof of causation, but neurologists describe the finding as "intriguing" — particularly for older adults who are already on these medications for bone health.

Read more →
New ResearchThe News International· 2026-11-15

Johns Hopkins Identifies Two Brain Regions That Show Alzheimer's Damage a Decade Early

Researchers at Johns Hopkins University have identified two brain regions — distinct from the hippocampus — that show measurable deterioration up to ten years before Alzheimer's disease becomes clinically detectable. The discovery could dramatically shift the window for early intervention, giving clinicians far more lead time to act. If validated, monitoring these regions could become standard in brain health screening for people in their 40s and 50s.

Read more →
Evidence CheckKevinMD· 2026-11-14

Dementia Prevention: What's Actually Proven — and What's Still a Hunch

A practicing physician gives an unusually honest accounting of the dementia prevention landscape, including the VALAD trial — in which valacyclovir failed to slow cognitive decline in 120 adults with early-stage Alzheimer's or biomarker-positive MCI, despite a compelling viral hypothesis. The piece separates genuinely evidence-backed strategies from plausible-but-unproven ones, including the author's own off-label prescribing habits. Worth reading if you're making real decisions about dementia risk management right now.

Read more →

Supplements & Compounds

Clinical TrialEuropean Heart Journal Open· 2026-11-14

STAMINA Trial: Aging-Biology Supplement Delivers Significant Vascular Improvements

A supplement formulated to target the biology of aging produced significant improvements in vascular function and blood pressure parameters in the STAMINA clinical study, published in European Heart Journal Open on November 4, 2026. Vascular aging is one of the most reliable upstream predictors of both cardiovascular disease and cognitive decline, making compounds that measurably slow it clinically relevant. Details on the specific formulation and effect sizes are worth reviewing before adding this to your stack.

Read more →
Evidence CheckPsyPost· 2026-11-14

CBG's Anti-Inflammatory Brain Claims Don't Hold Up in Lab Testing

Cannabigerol (CBG), a non-intoxicating cannabis compound widely sold as an anti-inflammatory supplement, showed inconsistent effects on brain immune cells in a new laboratory study — and most doses caused DNA strand breaks in isolated cells. This is a cell study, not a human trial, so clinical significance remains unclear. But if you're taking CBG specifically for brain inflammation benefits, the evidence base is considerably shakier than the marketing suggests.

Read more →
Aviado ResearchAviado Research· 2026-05-04

DHA Doesn't Just Reduce Inflammation — It Physically Rebuilds Your Cell Membranes

Most people think of omega-3s as circulating anti-inflammatories, but DHA works through a fundamentally different mechanism: it physically replaces pro-inflammatory fats like arachidonic acid in your cell membranes, structurally changing how your cells respond to inflammatory signals for weeks or months at a time. This membrane remodeling takes 8–12 weeks of consistent daily intake and requires 1–3g of DHA in triglyceride or phospholipid form — ethyl ester versions absorb significantly less effectively. Aviado Research explains why this makes DHA a long-game inflammation strategy, not a quick fix.

Read the full Aviado analysis →

Research & Papers

Clinical TrialMedical News Today· 2026-11-14

Two-Drug Cholesterol Therapy Reverses Artery Plaque More Effectively Than Statins Alone

A new clinical trial found that combining two cholesterol-lowering medications reduces — and may actually reverse — arterial plaque buildup to a degree that statins alone typically cannot achieve. More intensive lipid reduction appears to push beyond stabilizing plaque toward actively shrinking it, which could meaningfully lower the risk of cardiovascular events. The findings add momentum to growing evidence that targeting aggressively low LDL, not just reaching a "normal" range, is a worthwhile clinical goal.

Read more →

Lifestyle & Nutrition

Evidence CheckThe New York Times· 2026-11-14

The Obesity Paradox: Why a Little Extra Weight May Actually Protect Older Adults

A growing body of research challenges the assumption that weight guidelines designed for younger adults apply equally to people over 65. Some studies suggest that modest weight above standard "healthy" thresholds correlates with better survival outcomes in older populations — a pattern researchers are calling the obesity paradox. Dr. Blissmer and colleagues are now broadening their investigation beyond mortality to quality of life, with findings expected within the year.

Read more →
New ResearchLifespan.io· 2026-11-13

Why You Move Less as You Age: Scientists Pinpoint a Brain Mechanism Behind It

A new study in mice found that serotonin-producing neurons in a specific brain region become hyperactive with age, suppressing dopamine production — and with it, the motivation to exercise. This neurochemical shift may help explain the well-documented and self-reinforcing decline in physical activity that accompanies aging. The findings are in mice, so human translation isn't guaranteed, but they point toward a potentially targetable pathway for restoring exercise drive in older adults.

Read more →